FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1525802374> ?p ?o ?g. }

• W1525802374 endingPage "470" @default.
• W1525802374 startingPage "462" @default.
• W1525802374 abstract "This study investigates the pharmacokinetics and safety profile of Z-321, (4R)-3-(indan-2-ylacetyl)-4-(1-pyrrolidinyl-carbonyl)-1,3-thiazoli dine, a novel specific orally active prolyl endopeptidase (PEP) inhibitor. Following a preliminary safety evaluation wherein 2 subjects received 3.75 and 15 mg doses and 2 other subjects received 7.5 and 30 mg doses, 16 subjects were assigned to two groups of 8 subjects each. In each group, 6 subjects were to receive active treatment, and 1 or 2 subjects were to receive placebo treatment. One group received 60 mg under fasted and fed conditions. A separate group of 8 subjects received 60 mg of Z-321 or a placebo in a bid regimen for 6 days and the morning dose on day 7. The concentrations of Z-321 and its main metabolites--R- and S-sulfoxide; RR-, SS-, and RS-indanol; and indanolsulfoxides in plasma and urine--were determined by the HPLC method. In the multiple-dose study, the cholinesterase activity was gradually increased and reached above the normal range on day 8 in 3 of 6 subjects given Z-321 and gradually returned to the normal range after completion of dosing. The elevation of plasma cholinesterase activity was considered to be an action of Z-321, but this remains to be verified. In a single-dose study at a dose of 30 mg, headache and vomiting were observed in 1 of 6 subjects. In the multiple-dose study, slight skin itching and eczema in 3 and 2 of 6 subjects, respectively, and headache in 2 of 6 subjects were observed, but all symptoms were not severe. There were no other abnormal findings in objective signs and laboratory findings, including blood pressure, heart rate, electrocardiogram, body temperature, hematology, blood chemistry, and urinalysis. The Cmax of Z-321 at 30, 60, and 120 mg in the fasting state were 63.7 +/- 23.9, 102.0 +/- 43.1, and 543.3 +/- 437.0 ng/ml (mean +/- SD), respectively, at 0.9 hours after administration, and the t1/2 was about 1.8 hours. There were no dramatic changes in the pharmacokinetics of Z-321 in the presence of food. In the multiple-dose study, there was no drug accumulation trend in plasma. These results indicate that Z-321 has acceptable pharmacodynamic and pharmacokinetics profiles for clinical use without any serious adverse events, as verified in healthy young male volunteers." @default.
• W1525802374 created "2016-06-24" @default.
• W1525802374 creator A5011449748 @default.
• W1525802374 creator A5012000909 @default.
• W1525802374 creator A5012173587 @default.
• W1525802374 creator A5050298952 @default.
• W1525802374 creator A5064662913 @default.
• W1525802374 creator A5072602785 @default.
• W1525802374 creator A5088804804 @default.
• W1525802374 date "1999-05-01" @default.
• W1525802374 modified "2023-09-27" @default.
• W1525802374 title "Pharmacokinetics and Safety of Z‐321, a Novel Specific Orally Active Prolyl Endopeptidase Inhibitor, in Healthy Male Volunteers" @default.
• W1525802374 cites W17920185 @default.
• W1525802374 cites W1963418184 @default.
• W1525802374 cites W1965152824 @default.
• W1525802374 cites W1971440418 @default.
• W1525802374 cites W1972201579 @default.
• W1525802374 cites W1979392961 @default.
• W1525802374 cites W1982135023 @default.
• W1525802374 cites W2007684964 @default.
• W1525802374 cites W2011621580 @default.
• W1525802374 cites W2047953385 @default.
• W1525802374 cites W2059545303 @default.
• W1525802374 cites W2061727499 @default.
• W1525802374 cites W2077503584 @default.
• W1525802374 cites W2087526401 @default.
• W1525802374 cites W2095274534 @default.
• W1525802374 cites W2098003757 @default.
• W1525802374 cites W2145293838 @default.
• W1525802374 cites W2156899722 @default.
• W1525802374 cites W2316979973 @default.
• W1525802374 doi "https://doi.org/10.1177/009127009903900505" @default.
• W1525802374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10234593" @default.
• W1525802374 hasPublicationYear "1999" @default.
• W1525802374 type Work @default.
• W1525802374 sameAs 1525802374 @default.
• W1525802374 citedByCount "11" @default.
• W1525802374 countsByYear W15258023742013 @default.
• W1525802374 countsByYear W15258023742017 @default.
• W1525802374 countsByYear W15258023742020 @default.
• W1525802374 countsByYear W15258023742023 @default.
• W1525802374 crossrefType "journal-article" @default.
• W1525802374 hasAuthorship W1525802374A5011449748 @default.
• W1525802374 hasAuthorship W1525802374A5012000909 @default.
• W1525802374 hasAuthorship W1525802374A5012173587 @default.
• W1525802374 hasAuthorship W1525802374A5050298952 @default.
• W1525802374 hasAuthorship W1525802374A5064662913 @default.
• W1525802374 hasAuthorship W1525802374A5072602785 @default.
• W1525802374 hasAuthorship W1525802374A5088804804 @default.
• W1525802374 hasConcept C112705442 @default.
• W1525802374 hasConcept C126322002 @default.
• W1525802374 hasConcept C142724271 @default.
• W1525802374 hasConcept C149151106 @default.
• W1525802374 hasConcept C19720800 @default.
• W1525802374 hasConcept C197934379 @default.
• W1525802374 hasConcept C204787440 @default.
• W1525802374 hasConcept C27081682 @default.
• W1525802374 hasConcept C31896038 @default.
• W1525802374 hasConcept C42219234 @default.
• W1525802374 hasConcept C71924100 @default.
• W1525802374 hasConcept C98274493 @default.
• W1525802374 hasConceptScore W1525802374C112705442 @default.
• W1525802374 hasConceptScore W1525802374C126322002 @default.
• W1525802374 hasConceptScore W1525802374C142724271 @default.
• W1525802374 hasConceptScore W1525802374C149151106 @default.
• W1525802374 hasConceptScore W1525802374C19720800 @default.
• W1525802374 hasConceptScore W1525802374C197934379 @default.
• W1525802374 hasConceptScore W1525802374C204787440 @default.
• W1525802374 hasConceptScore W1525802374C27081682 @default.
• W1525802374 hasConceptScore W1525802374C31896038 @default.
• W1525802374 hasConceptScore W1525802374C42219234 @default.
• W1525802374 hasConceptScore W1525802374C71924100 @default.
• W1525802374 hasConceptScore W1525802374C98274493 @default.
• W1525802374 hasIssue "5" @default.
• W1525802374 hasLocation W15258023741 @default.
• W1525802374 hasLocation W15258023742 @default.
• W1525802374 hasOpenAccess W1525802374 @default.
• W1525802374 hasPrimaryLocation W15258023741 @default.
• W1525802374 hasRelatedWork W1964759623 @default.
• W1525802374 hasRelatedWork W1967453139 @default.
• W1525802374 hasRelatedWork W1982282930 @default.
• W1525802374 hasRelatedWork W2038418947 @default.
• W1525802374 hasRelatedWork W2058965590 @default.
• W1525802374 hasRelatedWork W2065722033 @default.
• W1525802374 hasRelatedWork W2132691174 @default.
• W1525802374 hasRelatedWork W2942467058 @default.
• W1525802374 hasRelatedWork W3003305233 @default.
• W1525802374 hasRelatedWork W3122926187 @default.
• W1525802374 hasVolume "39" @default.
• W1525802374 isParatext "false" @default.
• W1525802374 isRetracted "false" @default.
• W1525802374 magId "1525802374" @default.
• W1525802374 workType "article" @default.